The Expression and Significance of Serum Caveolin-1 in Patients with Kawasaki Disease

10.4103/CJP.CJP_71_19

Feng Zhu；Jing Huang；Xuliang Wang；Ping Li；Yaoyao Yan；Yunyun Zheng；Yue'e He；Tingting Wu；Yue Ren；Rongzhou Wu

Caveolin-1 ； coronary artery lesions ； intravenous immunoglobulin ； Kawasaki disease

The Chinese Journal of Physiology

63卷2期（2020 / 04 / 30）

90 - 94

英文

We investigated the expression of caveolin-1 (Cav-1) in Kawasaki disease (KD) and analyzed its relationship with coronary artery lesions (CALs). Cav-1 participated in the progression of CAL in KD. A total of 68 children with KD (23 with CALs), age matched with a fever control group (F, n = 28) and a normal control group (N, n = 24) were enrolled in this study. Cav-1 expression was detected using an enzyme-linked immunosorbent assay. The results are the following: (1) Compared with the F and N, Cav-1 expression was significantly increased in the children with KD (P ＜ 0.05); there was no significant difference in Cav-1 between the F and N. (2) The serum level of Cav-1 was significantly higher in children with KD and CALs during the acute phase than in children with KD without CALs (P ＜ 0.05). (3) Serum Cav-1 may be a biomarker that reflects CALs in children with KD based on a receiver operating characteristic (ROC) curve analysis. (4) Those children with KD who were given intravenous immunoglobulin (2 g/kg, 10-12 h) during the acute phase showed decreased expression of Cav-1 compared to the N. Conclusions are as follows: (1) The serum level of Cav-1 during the acute phase of KD increased significantly, while in KD patients with CALs the increase was even greater. (2) Based on our ROC curve analysis, Cav-1 may be a predictor of CALs in children with KD.

1. Beardsley, A,Fang, K,Mertz, H,Castranova, V,Friend, S,Liu, J(2005).Loss of caveolin-1 polarity impedes endothelial cell polarization and directional movement.J Biol Chem,280,3541-3547.
2. Braun-Dullaeus, RC,Mann, MJ,Dzau, VJ(1998).Cell cycle progression: New therapeutic target for vascular proliferative disease.Circulation,98,82-89.
3. Burns, JC,Franco, A(2015).The immunomodulatory effects of intravenous immunoglobulin therapy in Kawasaki disease.Expert Rev Clin Immunol,11,819-825.
4. Chen, SF,Liou, JY,Huang, TY,Lin, YS,Yeh, AL,Tam, K(2010).Caveolin-1 facilitates cyclooxygenase-2 protein degradation.J Cell Biochem,109,356-362.
5. Falcini, F,Capannini, S,Rigante, D(2011).Kawasaki syndrome: An intriguing disease with numerous unsolved dilemmas.Pediatr Rheumatol Online,9,17.
6. Frank, PG,Hassan, GS,Rodriguez-Feo, JA,Lisanti, MP(2007).Caveolae and caveolin-1: Novel potential targets for the treatment of cardiovascular disease.Curr Pharm Des,13,1761-1769.
7. Gadjeva, M,Paradis-Bleau, C,Priebe, GP,Fichorova, R,Pier, GB(2010).Caveolin‑1 modifies the immunity to Pseudomonas aeruginosa.J Immunol,184,296-302.
8. Galeotti, C,Kaveri, SV,Cimaz, R,Koné-Paut, I,Bayry, J(2016).Predisposing factors, pathogenesis and therapeutic intervention of Kawasaki disease.Drug Discov Today,21,1850-1857.
9. Garrean, S,Gao, XP,Brovkovych, V,Shimizu, J,Zhao, YY,Vogel, SM(2006).Caveolin‑1 regulates NF‑kappaB activation and lung inflammatory response to sepsis induced by lipopolysaccharide.J Immunol,177,4853-4860.
10. Hu, G,Ye, RD,Dinauer, MC,Malik, AB,Minshall, RD(2008).Neutrophil caveolin‑1 expression contributes to mechanism of lung inflammation and injury.Am J Physiol Lung Cell Mol Physiol,294,L178-L186.
11. Newburger, JW,Takahashi, M,Gerber, MA,Gewitz, MH,Tani, LY,Burns, JC(2004).Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the committee on rheumatic fever, endocarditis, and Kawasaki disease, council on cardiovascular disease in the young, American heart association.Pediatrics,114,1708-1733.
12. Pang, Q,Zhang, H,Chen, Z,Wu, Y,Bai, M,Liu, Y(2017).Role of caveolin-1/vascular endothelial growth factor pathway in basic fibroblast growth factor-induced angiogenesis and neurogenesis after treadmill training following focal cerebral ischemia in rats.Brain Res,1663,9-19.
13. Qin, L,Zhu, N,Ao, BX,Liu, C,Shi, YN,Du, K(2016).Caveolae and caveolin‑1 integrate reverse cholesterol transport and inflammation in atherosclerosis.Int J Mol Sci,17,429.
14. Rothberg, KG,Heuser, JE,Donzell, WC,Ying, YS,Glenney, JR,Anderson, RGW(1992).Caveolin, a protein component of caveolae membrane coats.Cell,68,673-682.
15. Salem, AF,Bonuccelli, G,Bevilacqua, G,Arafat, H,Pestell, RG,Sotgia, F(2011).Caveolin‑1 promotes pancreatic cancer cell differentiation and restores membranous E-cadherin via suppression of the epithelial-mesenchymal transition.Cell Cycle,10,3692-3700.
16. Shulman, ST(1989).IVGG therapy in Kawasaki disease: Mechanism(s) of action.Clin Immunol Immunopathol,53,S141-S146.
17. Sonveaux, P,Martinive, P,DeWever, J,Batova, Z,Daneau, G,Pelat, M(2004).Caveolin-1 expression is critical for vascular endothelial growth factor-induced ischemic hindlimb collateralization and nitric oxide-mediated angiogenesis.Circ Res,95,154-161.
18. Tsujii, N,Tsuda, E,Kanzaki, S,Ishizuka, J,Nakashima, K,Kurosaki, K(2017).Late wall thickening and calcification in patients after Kawasaki disease.J Pediatr,181,167-7100.
19. Voghel, G,Thorin-Trescases, N,Farhat, N,Nguyen, A,Villeneuve, L,Mamarbachi, AM(2007).Cellular senescence in endothelial cells from atherosclerotic patients is accelerated by oxidative stress associated with cardiovascular risk factors.Mech Ageing Dev,128,662-671.
20. Yeung, RS(2010).Kawasaki disease: Update on pathogenesis.Curr Opin Rheumatol,22,551-560.
21. Zhao, YY,Zhao, YD,Mirza, MK,Huang, JH,Potula, HH,Vogel, SM(2009).Persistent eNOS activation secondary to caveolin‑1 deficiency induces pulmonary hypertension in mice and humans through PKG nitration.J Clin Invest,119,2009-2018.